Stable oxytocin pharmaceutical composition and preparation method thereof
By combining mannitol, which removes the reducing sugars, with oxytocin, and controlling it between pH 4.5-5.5, combined with the freeze-drying process, the problem of poor stability of oxytocin is solved, and a stable oxytocin drug is achieved The preparation of the composition reduces storage and transportation costs and simplifies the preparation process.
Patent Information
- Application Number
- CN201811407754.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2018-11-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2038-11-23
AI Technical Summary
As a polypeptide drug, oxytocin has poor stability and is prone to degradation during storage and transportation, resulting in unqualified formulations. The use of existing antioxidants and pH regulators increases the amount and cost of auxiliary materials.
By preparing mannitol that removes reducing sugars twice and combines with oxytocin, adding water for injection and citric acid, the pH adjuster, to control the pH value between 4.5-5.5, and using freeze-drying process to prepare stable oxytocin powder injections .
It significantly improves the stability of oxytocin drugs, reduces storage and transportation costs, and simplifies the preparation process, ensuring the stability of the drug at room temperature and simple and clear prescription ingredients.
Smart Images

Figure CN109745544B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a stable oxytocin pharmaceutical composition and a preparation method thereof. Background Art
[0002] Oxytocin is a polypeptide composed of 9 amino acid residues, and its chemical structure is:
[0003] H-Cys-Tyr-Ile-Glu(NH2)-Asp(NH2)-Cys-Pro-Leu-Gly-NH2, which contains a disulfide bond in its chemical structure.
[0004]
[0005] Oxytocin is a commonly used gynecological drug, mainly used for induction of labor, expedited labor, postpartum hemorrhage and uterine bleeding caused by poor uterine repositioning. Since oxytocin is a polypeptide drug with poor stability and easy to be degraded, it is easy to produce unqualified products during long-term storage and transportation.
[0006] The Maillard reaction, also known as the "non-enzymatic browning reaction", is a non-enzymatic browning reaction widely found in the food industry. It is a reaction between carbonyl compounds (reducing sugars) and amino compounds (amino acids and proteins). After a complex process, it eventually produces a brown or even black macromolecular substance called melanoidin or pseudo-melanin, so it is also called the carbonyl-amino reaction. The Maillard reaction can occur when the temperature is 20-25°C; the reaction is easy to occur when the water content is 10%-15%; when the pH value is above 3, the reaction accelerates as the pH value increases. The existing commercially available mannitol excipients mostly contain 0.05%-0.2% reducing sugars (glucose, fructose, etc.). These impurities react slowly with oxytocin to produce the Maillard reaction, which is the root cause of the instability of oxytocin preparations.
[0007] According to existing reports, in order to improve the stability of oxytocin preparations, medical personnel add a variety of antioxidants, preservatives and various pH adjusters to their prescriptions. Generally, in the production process of injections, in addition to the active ingredients, it is better to add a small amount of excipients. In order to overcome the above defects, we have developed a stable oxytocin pharmaceutical composition based on a large number of experiments. Summary of the invention
[0008] The purpose of the present invention is to provide a pharmaceutical composition containing stable oxytocin and a preparation method thereof, which has good stability, the composition has stable properties, can be stored and transported at room temperature, and the prescription ingredients are simple and clear, and the preparation method is simple and easy with low cost.
[0009] The present invention is achieved in this way: a stable oxytocin pharmaceutical composition comprises oxytocin, mannitol from which reducing sugars have been removed for a second time, water for injection and a pH regulator; the mannitol from which reducing sugars have been removed for a second time is obtained by re-dissolving, reacting, filtering, separating with molecular sieves, concentrating and drying the mannitol.
[0010] Oxytocin 100000 IU; mannitol with secondary removal of reducing sugar 100 g; water for injection added to 10000 ml, pH value range between 4.5-5.5.
[0011] The pH regulator is citric acid or tartaric acid.
[0012] The preparation method of the stable oxytocin pharmaceutical composition comprises the following steps:
[0013] 1) Preparation of mannitol with secondary removal of reducing sugars: adding water for injection to mannitol until the mannitol is completely dissolved, adding amino acids at a mass concentration of 2‰, and keeping warm at 80°C for 30 minutes, centrifuging to obtain the supernatant, passing the supernatant through a molecular sieve, and detecting by HPLC, collecting the eluate containing mannitol, and combining them to obtain the mannitol with secondary removal of reducing sugars to be used;
[0014] 2) adding a prescribed amount of oxytocin to the mannitol from which reducing sugars have been removed for the second time, and stirring evenly to obtain solution A;
[0015] 3) Add water for injection to the total amount of solution A and control the pH value to be between 4.5 and 5.5 to obtain solution B;
[0016] 4) Solution B is filtered through 0.45 μm and 0.22 μm filters, packaged into 1 ml portions and placed in a freeze dryer for freeze drying to obtain oxytocin powder injection.
[0017] All the above steps are carried out according to the aseptic production process.
[0018] The freeze drying described in step 4) comprises the following steps:
[0019] A. Pre-freezing: After the temperature of the filtered and packaged solution B and the freeze dryer plate layer has been pre-cooled to -45°C, heat it to -20°C and keep it for 1-2 hours, then cool it down to -45°C and keep it for 2 hours;
[0020] B. Primary drying: Maintain vacuum at 0 bar, raise the temperature to -35℃ and keep for 4-5 hours for primary drying;
[0021] C. Secondary drying: After completing the primary drying, raise the plate temperature to 0°C within 1 hour, keep it warm for 30 minutes, then raise the temperature to 25°C within 1 hour, keep it warm for 4 hours to complete the entire freeze-drying process.
[0022] Due to the adoption of the above technical scheme, the inventors of the present invention have found that the specially treated pharmaceutical composition consisting of mannitol and oxytocin has very excellent stability, is not easily degraded during storage and transportation at room temperature, can significantly reduce storage and transportation costs, and has important clinical significance. The preparation method is simple and easy with low cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 It is a stability test comparison chart of the present invention. DETAILED DESCRIPTION
[0024] The present invention is further illustrated by the following examples, but the examples do not limit the scope of the present invention.
[0025] Embodiment: A stable oxytocin pharmaceutical composition comprises 100,000 IU of oxytocin, 100 g of mannitol from which reducing sugars have been removed for a second time, and water for injection up to 10,000 ml; and citric acid is used as a pH regulator.
[0026] The preparation method of the stable oxytocin pharmaceutical composition comprises the following steps:
[0027] 1) Preparation of mannitol from which reducing sugars have been removed for the second time: adding water for injection to mannitol until the mannitol is completely dissolved, adding amino acids at a mass concentration of 2‰, and keeping warm at 80°C for 30 minutes, centrifuging to obtain the supernatant, passing the supernatant through a molecular sieve, and detecting by HPLC, collecting the eluate containing mannitol, and combining them to obtain the mannitol from which reducing sugars have been removed for the second time to be used;
[0028] 2) adding a prescribed amount of oxytocin to the mannitol from which reducing sugars have been removed for the second time, and stirring evenly to obtain solution A;
[0029] 3) Add water for injection to the total amount of solution A and control the pH value to be between 4.5 and 5.5 to obtain solution B;
[0030] 4) Solution B is filtered through 0.45 μm and 0.22 μm filters, packaged into 1 ml portions and placed in a freeze dryer for freeze drying to obtain oxytocin powder injection.
[0031] All the above steps are carried out according to the aseptic production process.
[0032] The freeze drying described in step 4) comprises the following steps:
[0033] A. Pre-freezing: After the temperature of the filtered and packaged solution B and the freeze dryer plate layer has been pre-cooled to -45°C, heat it to -20°C and keep it for 1-2 hours, then cool it down to -45°C and keep it for 2 hours;
[0034] B. Primary drying: Maintain vacuum at 0 bar, raise the temperature to -35℃ and keep for 4-5 hours for primary drying;
[0035] C. Secondary drying: After completing the primary drying, raise the plate temperature to 0°C within 1 hour, keep it warm for 30 minutes, then raise the temperature to 25°C within 1 hour, keep it warm for 4 hours to complete the entire freeze-drying process.
[0036] In this embodiment, by adjusting the pH value, oxytocin pharmaceutical compositions with pH values of 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, and 6.5 were prepared respectively.
[0037] Their stability at 25°C and 40°C for 6 months was investigated respectively. The experimental results are shown in Tables 1 and 2.
[0038] Table 1 Stability data of oxytocin preparations with different pH values at 25°C
[0039]
[0040] Table 2 Stability data of oxytocin preparations with different pH values at 40°C
[0041]
[0042] Combining the data in Table 1 and Table 2, it can be concluded that the relatively stable pH value range of the oxytocin pharmaceutical composition under this prescription is between 4.5 and 5.5. A pH value higher or lower than this range will be detrimental to the stability of oxytocin.
[0043] Commercially available medicinal mannitol and purified mannitol were prepared into saturated solutions. Saturated glucose solution was used as a positive control, and Fehling's reagent without any sugar added was used as a negative control. The experimental results are shown in Figure 2. Figure 1 shown.
[0044] Comparative Example: An oxytocin pharmaceutical composition comprises oxytocin 100000 IU, commercially available ordinary mannitol 100 g and water for injection added to 10000 ml; and citric acid is used as a pH regulator.
[0045] The stability of oxytocin preparations made from mannitol from different sources was investigated at 25°C and 40°C for 6 months. The experimental results are shown in Tables 3 and 4.
[0046] Table 3 Stability data of oxytocin preparations prepared by the prescription at 25℃
[0047]
[0048]
[0049] Table 4 Stability data of oxytocin preparations prepared by the prescription at 40°C
[0050]
[0051] The results in Tables 3 and 4 show that the stability of the commercially available oxytocin preparations made from mannitol is much lower than that of the oxytocin preparations made from the purified mannitol of the present invention, whether at 25° C. or 40° C.
[0052] The above embodiments are only intended to help understand the method and core concept of the present invention. It should be noted that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention. These all fall within the scope of protection of the present invention.
Claims
1. A method for preparing a stable oxytocin pharmaceutical composition, Features: The following steps are involved: 1) Preparation of mannitol with secondary removal of reducing sugars: Add injection water to mannitol until the mannitol is completely dissolved, add amino acids at a mass concentration of 2‰, keep warm at 80°C for 30 min, centrifuge to obtain the supernatant, pass the supernatant through a molecular sieve, detect by HPLC, collect the eluate containing mannitol, combine them, and obtain the mannitol with secondary removal of reducing sugars to be used; 2) Add 100,000 IU of oxytocin to a solution containing 100 g of mannitol from which reducing sugars have been removed for the second time, and stir evenly to obtain solution A; 3) Add water for injection to solution A to a total volume of 10,000 ml and control the pH value between 4.5 and 5.5 to obtain solution B; 4) Solution B is filtered through 0.45 μm and 0.22 μm filters, packaged into 1 ml portions and placed in a freeze dryer for freeze drying to obtain oxytocin powder injection.
2. The preparation method according to claim 1, Features: All the above steps are carried out according to the aseptic production process.
3. The preparation method according to claim 2, Features: The freeze drying described in step 4) comprises the following steps: A. Prefreezing: After the temperature of the filtered and packaged solution B and the freeze dryer plate layer has dropped to -45°C, heat it to -20°C and keep it for 1-2 hours, then cool it down to -45°C and keep it for 2 hours; B. Primary drying: Maintain vacuum degree 0 bar, raise temperature to -35℃ and keep warm for 4-5 hours, and perform primary drying; C. Secondary drying: After the primary drying is completed, the plate temperature is raised to 0°C within 1 hour, kept warm for 30 minutes, and then raised to 25°C within 1 hour, kept warm for 4 hours to complete the entire freeze-drying process.
